



Please see the Important Safety Information and accompanying full Prescribing Information.

You're invited to a presentation^a:

ZYNLONTA® (loncastuximab tesirine-lpyl), the First-and-Only CD19-Targeted ADC, for the Treatment of Adults With R/R DLBCL After 2 or More Lines of Systemic Therapy

Presenter

Edward Pearson, MD

Date

10/22/2026 at 5:30 PM Central

Location

Las Brisas
4701 112th St.
Lubbock, Texas 79424

RSVP

Terry Sweeney
terry.sweeney@adctherapeutics.com
405-590-2278

^aThis program is intended only for healthcare professionals (HCPs) in the relevant therapeutic area. Guests, including spouses, partners, and family members of attendees or speakers, may not attend or partake of any meal offered unless independently qualified to attend. This is a promotional program sponsored by ADC Therapeutics and does not qualify for Continuing Medical Education (CME) or continuing education (CE) credit. ADC Therapeutics reports certain payments and other transfers of value, including meals provided to HCPs, pursuant to applicable federal and/or state laws. If you are an HCP where your employment or state of licensure limits your ability to accept a meal, please do not accept any meal offered with this program. It is recommended that you consult your legal or ethics advisor regarding any applicable limitations.



ZYNLONTA is a registered trademark of ADC Therapeutics SA.
US-Comm-LTX-00194 November 2022
© 2022 ADC Therapeutics SA. All rights reserved.